Women in England with an aggressive form of breast cancer will get access to an AstraZeneca Plc and Daiichi Sankyo Co. drug on the National Health Service after an agreement with the regulator, according to Bloomberg.
Women in England with an aggressive form of breast cancer will get access to an AstraZeneca Plc and Daiichi Sankyo Co. drug on the National Health Service after an agreement with the regulator, according to Bloomberg.